A CD4+ T lymphocyte–specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity
Journal of Clinical Investigation · 01.08.2025 · 135 (15)
DOI: 10.1172/jci191119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.08.2025. Verfasst von Yihan Yao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Bone Marrow Transplantation Center and. Hauptthemen laut MEDLINE: Phosphate-Binding Proteins, CD4-Positive T-Lymphocytes, Receptors, Antigen, T-Cell, Interleukin-2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Gasdermin (GSDM) family proteins mediate tumor pyroptosis and impact cancer progression, but other than that, their involvement in the tumor immune microenvironment remains largely unknown. Here, we show that activation of GSDMD in human tumor specimens mainly occurs in tumor-infiltrating leukocytes. Significantly, GSDMD deficiency or its inactivation in CD4 + T cells disabled CD8 + T cell–mediated antitumor immunity and caused tumor outgrowth in mice. Further study uncovered that, via inducing IL-2 production, GSDMD was required for CD4 + T cells to provide help to CD8 + T cell function. Mechanistically, GSDMD was cleaved by TCR stimulation–activated caspase-8 to form GSDMD-N pores, which enhanced Ca 2+ influx for IL-2 induction. Moreover, GSDMD activation and function were conserved in human CD4 + T cells and associated with favorable prognosis and improved response to anti–PD-1 immunotherapy in colonic and pancreatic cancer. We believe this study identifies a new nonpyroptotic role of GSDMD in tumor immunity, proposing GSDMD as a potential target for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Immunology and Bone Marrow Transplantation Center and.
- Department of Colorectal Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Radiation Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Institute of Immunology and Department of Respiratory Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Yao, Y., Wang, L., Jiang, W., Wang, N., Li, M., Lin, W., Zhang, T., Sheng, W., & Wang, X. (2025). A CD4+ T lymphocyte–specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity. Journal of Clinical Investigation, 135(15). https://doi.org/10.1172/jci191119
Vancouver
Yao Y, Wang L, Jiang W, Wang N, Li M, Lin W, et al. A CD4+ T lymphocyte–specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity. Journal of Clinical Investigation. 2025;135(15). doi:10.1172/jci191119
BibTeX
@article{Yao2025,
author = {Yao, Yihan and Wang, Lingling and Jiang, Weiqin and Wang, Ning and Li, Mengjie and Lin, Wenlong and Zhang, Ting and Sheng, Wanqiang and Wang, Xiaojian},
title = {A CD4+ T lymphocyte–specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {15},
doi = {10.1172/jci191119}
}
EUVIMED